Your browser is no longer supported. Please, upgrade your browser.
Settings
PBYI Puma Biotechnology, Inc. daily Stock Chart
PBYI [NASD]
Puma Biotechnology, Inc.
Index- P/E- EPS (ttm)-6.53 Insider Own11.30% Shs Outstand39.49M Perf Week-3.38%
Market Cap2.09B Forward P/E114.89 EPS next Y0.46 Insider Trans-0.35% Shs Float32.76M Perf Month3.73%
Income-243.40M PEG- EPS next Q-1.26 Inst Own95.70% Short Float8.29% Perf Quarter-24.34%
Sales94.20M P/S22.16 EPS this Y5.20% Inst Trans-1.97% Short Ratio3.62 Perf Half Y-44.34%
Book/sh1.52 P/B34.77 EPS next Y112.10% ROA-141.20% Target Price92.33 Perf Year-38.87%
Cash/sh- P/C- EPS next 5Y- ROE-314.10% 52W Range47.00 - 136.90 Perf YTD-46.54%
Dividend- P/FCF- EPS past 5Y-18.10% ROI-287.20% 52W High-61.40% Beta0.07
Dividend %- Quick Ratio1.90 Sales past 5Y- Gross Margin87.30% 52W Low12.45% ATR2.32
Employees318 Current Ratio1.90 Sales Q/Q- Oper. Margin- RSI (14)47.32 Volatility4.59% 4.23%
OptionableYes Debt/Eq0.85 EPS Q/Q67.30% Profit Margin- Rel Volume0.81 Prev Close52.35
ShortableYes LT Debt/Eq0.85 EarningsMay 09 AMC Payout- Avg Volume750.17K Price52.85
Recom2.20 SMA202.15% SMA50-7.31% SMA200-37.46% Volume607,126 Change0.96%
May-11-18Reiterated Stifel Buy $95 → $87
Nov-10-17Reiterated RBC Capital Mkts Sector Perform $92 → $108
Nov-10-17Reiterated Citigroup Buy $156 → $164
Oct-02-17Reiterated Stifel Buy $110 → $130
Sep-11-17Reiterated Credit Suisse Outperform $118 → $136
Jul-10-17Resumed Leerink Partners Outperform $115
Jun-06-17Reiterated RBC Capital Mkts Sector Perform $60 → $88
May-25-17Reiterated RBC Capital Mkts Sector Perform $40 → $60
Mar-02-17Reiterated RBC Capital Mkts Sector Perform $48 → $17
Sep-22-16Reiterated Credit Suisse Outperform $54 → $111
Sep-21-16Upgrade Stifel Hold → Buy $61 → $88
Mar-29-16Downgrade RBC Capital Mkts Outperform → Sector Perform $103 → $36
Jan-21-16Initiated Credit Suisse Outperform
Dec-14-15Upgrade Citigroup Neutral → Buy
Sep-03-15Initiated Citigroup Neutral
Aug-27-15Initiated JP Morgan Overweight $122
Jan-23-15Initiated RBC Capital Mkts Outperform $282
Aug-19-14Resumed Stifel Hold
Jul-23-14Reiterated UBS Buy $125 → $325
Dec-19-13Reiterated UBS Buy $61 → $125
Jun-20-18 04:28PM  Former Puma Biotech executive gets U.S. prison term for insider trading Reuters
Jun-18-18 08:30AM  Champions Oncology Partners with Puma Biotechnology and NSABP Foundation on Metastatic Breast and Colon Cancer Co-clinical PDX Studies PR Newswire
Jun-15-18 08:20AM  Today's Research Reports on Trending Tickers: Puma Biotechnology and bluebird bio ACCESSWIRE
Jun-12-18 07:50AM  Detailed Research: Economic Perspectives on Amphenol, Hologic, Newell Brands, Ciena, SAExploration, and Puma Biotechnology What Drives Growth in Today's Competitive Landscape GlobeNewswire
Jun-02-18 09:00AM  Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2018 ASCO Annual Meeting Business Wire
May-30-18 04:05PM  Puma Biotechnology to Present at Jefferies Global Healthcare Conference Business Wire
May-17-18 10:02PM  Edited Transcript of PBYI earnings conference call or presentation 9-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-16-18 08:20AM  Today's Research Reports on Trending Tickers: Puma Biotechnology and Amicus Therapeutics ACCESSWIRE
May-11-18 08:10AM  Todays Research Reports on Stocks to Watch: Puma Biotechnology and Neovasc ACCESSWIRE
May-10-18 01:06PM  Here's Why Puma Biotechnology Inc. Is Sinking Today Motley Fool -20.67%
May-09-18 05:49PM  Puma Biotech: 1Q Earnings Snapshot Associated Press
04:05PM  Puma Biotechnology Reports First Quarter 2018 Financial Results Business Wire
May-08-18 04:15PM  Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference 2018 Business Wire
May-07-18 08:42AM  Puma Biotech (PBYI) to Report Q1 Earnings: What to Expect? Zacks
Apr-30-18 08:20AM  Today's Research Reports on Trending Tickers: Neovasc and Puma Biotechnology ACCESSWIRE -6.59%
Apr-25-18 04:15PM  Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results Business Wire
Apr-03-18 08:45AM  Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America Business Wire
Apr-02-18 11:19AM  Puma's Shares Fall This Year Post a Solid 2017: Here's Why Zacks -5.36%
08:45AM  NCCN Guidelines for Central Nervous System Cancers Include NERLYNX® (neratinib) in Combination With Capecitabine or Paclitaxel as Treatment Options for Patients With Breast Cancer Brain Metastases Business Wire
04:38AM  Puma Biotechnology (PBYI) Up 10.2% Since Earnings Report: Can It Continue? Zacks
Mar-29-18 11:51AM  Puma Biotechnology Inc (NASDAQ:PBYI) Is Trading At A 47% Discount Simply Wall St.
Mar-28-18 11:00AM  Robbins Geller Rudman & Dowd LLP Announces Pending Class Action in the Puma Biotechnology, Inc. Litigation Business Wire
Mar-09-18 08:42AM  Does Puma Biotechnology Incs (NASDAQ:PBYI) -5.79% Earnings Drop Reflect A Longer Term Trend? Simply Wall St.
Mar-06-18 04:15PM  Puma Biotechnology to Present at Cowens Annual Healthcare Conference Business Wire
Mar-02-18 05:51PM  Why Puma Biotechnology Shares Jumped 15% Today Motley Fool +15.06%
02:21PM  Edited Transcript of PBYI earnings conference call or presentation 1-Mar-18 9:30pm GMT Thomson Reuters StreetEvents
11:37AM  Puma (PBYI) Q4 Loss Narrower Than Expected, Shares Down Zacks
Mar-01-18 05:02PM  Puma Biotech reports 4Q loss Associated Press -5.51%
04:05PM  Puma Biotechnology Reports Fourth Quarter and Full Year 2017 Financial Results Business Wire
12:00PM  Puma Biotechnology, Inc. to Host Earnings Call ACCESSWIRE
Feb-27-18 07:20AM  Blog Exposure - CHMP Recommended Against Approval of Puma Biotech's Neratinib for Extended Adjuvant Treatment of HER2-Positive Breast Cancer ACCESSWIRE
Feb-26-18 10:06AM  Heres Whats Moving KemPharm And Puma Biotechnology Market Exclusive
Feb-23-18 07:30AM  Puma Biotechnology Receives Results of CHMP Formal Decision for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer Business Wire
Feb-20-18 08:30AM  New Research Coverage Highlights SunCoke Energy Partners, Carrols Restaurant Group, First Financial, Emerson Electric, Puma Biotechnology, and Amgen Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Feb-15-18 04:15PM  Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results Business Wire
08:10AM  Todays Research Reports on Trending Tickers: Nektar Therapeutics and Puma Biotechnology ACCESSWIRE
Feb-07-18 04:15PM  Puma Biotechnology to Present at LEERINK Partners Global Healthcare Conference Business Wire
Feb-02-18 10:00AM  Puma, CANbridge Team Up to Commercialize Nerlynx in China Zacks
Feb-01-18 04:15PM  Puma Biotechnology and CANbridge Life Sciences Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Greater China Business Wire
Jan-31-18 01:16PM  Puma Biotechnology Announces Publication of Results from Phase II SUMMIT Basket Trial Evaluating Neratinib in HER2 and HER3 Mutant Cancers Business Wire
09:17AM  Puma & Medison Team Up to Commercialize Nerlynx in Israel Zacks
Jan-30-18 04:15PM  A Licensing Agreement Won't Protect This Biotech From A Takeover Investor's Business Daily
08:39AM  Do Options Traders Know Something About Puma Biotechnology (PBYI) Stock We Don't? Zacks
08:15AM  Puma Biotechnology and Medison Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Israel Business Wire
Jan-29-18 04:20PM  Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jan-25-18 08:00AM  Todays Research Reports on Stocks to Watch: Valeant Pharmaceuticals and Puma Biotechnology ACCESSWIRE +5.26%
Jan-24-18 05:20PM  ICYMI: MicroCap Trading Ideas, Puma Biotech, A Valeant Bear Call Benzinga -28.82%
04:44PM  Why Texas Instruments, Puma Biotechnology, and Delta Air Lines Slumped Today Motley Fool
03:22PM  EU Unlikely to Approve Puma's Nerlynx in 2018, Stock Down Zacks
02:11PM  What Happened To Puma Biotechnology? Forbes
11:04AM  Here's Why Puma Biotechnology Inc. Is Getting Beaten Down Today Motley Fool
10:34AM  Puma Biotechnology Inc: A European Approval for Neratinib Seems Unlikely SmarterAnalyst
10:13AM  With EU Approval For Puma Biotech's Breast Cancer Drug Unlikely, Cowen Downgrades Benzinga
09:09AM  Heres Whats Moving Amarin Corporation and Puma Biotechnology Market Exclusive
09:02AM  How Is Kisqali Positioned for 2018? Market Realist
07:24AM  Puma Biotech shares plummet after 'concerning turn' in Europe MarketWatch
Jan-23-18 04:37PM  Puma Biotech shares drop more than 20% as European OK of breast cancer drug unlikely MarketWatch
04:15PM  Puma Biotechnology Announces Results of CHMP Oral Explanation for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer Business Wire
Jan-16-18 09:03AM  Why is Puma (PBYI) Stock Up More than 150% in a Year's Time? Zacks -8.46%
Jan-12-18 09:04AM  Biotech Updates: Aradigm Corporation & Puma Biotechnology Market Exclusive
Jan-10-18 01:37PM  Perjeta Could Significantly Boost Roches Revenue Growth in 2018 Market Realist
07:42AM  How Should You Think About Puma Biotechnology Incs (NASDAQ:PBYI) Risks? Simply Wall St.
Jan-05-18 04:39PM  Why These 3 Biotech Stocks Could Outperform Their Peers In 2018 Investor's Business Daily
Dec-15-17 08:35AM  What You Must Know About Puma Biotechnology Incs (NASDAQ:PBYI) Financial Health Simply Wall St.
Dec-14-17 04:15PM  Puma Biotechnology Added to NASDAQ Biotechnology Index Business Wire -5.23%
08:10AM  Todays Research Reports on Stocks to Watch: Puma Biotechnology and Intercept Pharmaceuticals ACCESSWIRE
Dec-13-17 04:15PM  Puma Biotechnology Announces Meeting of Scientific Advisory Group on Oncology in Europe to Review Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer Business Wire +5.62%
Dec-12-17 04:15PM  Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer Business Wire
09:35AM  Update in Lawsuit for Investors in Puma Biotechnology Inc (NYSE:PBYI) shares announced by Shareholders Foundation GlobeNewswire
Dec-11-17 08:45AM  Puma Biotechnology Announces Positive Outcome of European Opposition Proceedings Business Wire
Dec-08-17 11:47AM  Puma (PBYI) Stock Up More than 200% This Year: Here's Why Zacks
Dec-07-17 07:13PM  An Intrinsic Value Calculation For Puma Biotechnology Inc (PBYI) Shows Its 48.79% Undervalued Simply Wall St. +7.09%
Dec-06-17 03:07PM  Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2017 San Antonio Breast Cancer Symposium Business Wire
Dec-04-17 08:20AM  Analysis: Positioning to Benefit within Emerson Electric, Puma Biotechnology, Amgen, SunCoke Energy Partners, Carrols Restaurant Group, and First Financial Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire -7.40%
Nov-27-17 09:10AM  Breaking Down Puma Biotechnology Incs (PBYI) Ownership Structure Simply Wall St.
Nov-23-17 08:42AM  Puma Inks License Deal to Commercialize Cancer Drug Nerlynx Zacks
Nov-22-17 09:30AM  New Early- Breast Cancer Drug to be Made Available in Australia, New Zealand and South East Asia Following License Deal PR Newswire
09:15AM  Puma Biotechnology and Specialised Therapeutics Asia Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Australia, New Zealand and South East Asia Business Wire
Nov-16-17 07:10AM  Corporate News Blog - Puma Biotechnologys 5-Year Analysis of Phase-III ExteNET Study Gets Published in The Lancet Oncology ACCESSWIRE
Nov-14-17 07:50AM  Featured Company News - Blueprint Medicines Announced New Data from Ongoing Phase-1 Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors ACCESSWIRE
Nov-13-17 06:34PM  Puma Biotechnologys 5-Year Analysis of Phase III ExteNET Study Published Online in The Lancet Oncology Business Wire
08:10AM  Todays Research Reports on Stocks to Watch: Dynavax Technologies and Puma Biotechnology ACCESSWIRE
Nov-10-17 06:32PM  Puma Biotechnology Is Down 19% -- Is Its Stock a Bargain? Motley Fool -19.03%
04:25PM  Why This Biotech Crashed Despite Topping Breast Cancer Drug Sales Investor's Business Daily
02:25PM  Should You Worry About Puma Biotechnology Incs (PBYI) CEO Salary Level? Simply Wall St.
09:04AM  Puma (PBYI) Falls Despite Narrower-Than-Expected Q3 Loss Zacks
Nov-09-17 10:51PM  Edited Transcript of PBYI earnings conference call or presentation 9-Nov-17 9:30pm GMT Thomson Reuters StreetEvents
05:53PM  Puma Biotech reports 3Q loss Associated Press
04:49PM  Puma Biotechnology shares down 8% after quartely results MarketWatch
04:28PM  Puma Biotechnology Flops Despite Topping Sales, Loss Expectations Investor's Business Daily
04:07PM  Puma Biotechnology Reports Third Quarter 2017 Financial Results Business Wire
12:30PM  Puma Biotechnology, Inc. to Host Earnings Call ACCESSWIRE
Nov-08-17 04:15PM  Puma Biotechnology to Present at Stifel Healthcare Conference Business Wire
08:54AM  Should You Buy Puma Biotechnology (PBYI) Ahead of Earnings? Zacks
08:16AM  Key Predictions for Q3 Earnings Reports of PBYI, XON, LGND Zacks
Nov-07-17 09:51AM  Puma (PBYI) Q3 Earnings: Will it Surpass Estimates Again? Zacks
Nov-06-17 04:00PM  Puma Biotech secures $100 million loan to market its breast cancer drug American City Business Journals
08:00AM  Factors of Influence in 2018, Key Indicators and Opportunity within United Bankshares, Papa John's, Puma Biotechnology, TiVo, Sanderson Farms, and Aspen Technology New Research Emphasizes Economic Growth GlobeNewswire
Nov-02-17 04:31PM  Former Puma Biotech executive pleads guilty to insider trading Reuters
04:20PM  Puma Biotechnology Secures $100 Million Term Loan from Silicon Valley Bank and Oxford Finance Business Wire
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous)). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
EYLER CHARLES RSEE REMARKSJun 01Sale53.001,21164,18335,816Jun 04 05:08 PM
Lo StevenChief Commercial OfficerJan 22Sale92.851,858172,51525,362Jan 24 04:38 PM
BRYCE RICHARD PAULSR VP, CLINICAL RESEARCH & DEVJan 22Sale92.751,860172,51525,379Jan 24 04:33 PM
AUERBACH ALAN HPRESIDENT AND CEOJan 22Sale92.7510,692991,6834,155,931Jan 24 04:30 PM
EYLER CHARLES RSEE REMARKSDec 01Sale105.461,322139,42428,696Dec 05 04:06 PM
BRYCE RICHARD PAULSR VP, CLINICAL RESEARCH & DEVSep 29Option Exercise11.3015,000169,50042,239Oct 02 04:24 PM
BRYCE RICHARD PAULSR VP, CLINICAL RESEARCH & DEVSep 29Sale120.0015,0001,800,00027,239Oct 02 04:24 PM
BRYCE RICHARD PAULSR VP, CLINICAL RESEARCH & DEVSep 07Option Exercise11.3014,000158,20041,239Sep 08 04:11 PM
BRYCE RICHARD PAULSR VP, CLINICAL RESEARCH & DEVSep 07Sale100.1014,0001,401,40027,239Sep 08 04:11 PM
BRYCE RICHARD PAULSR VP, CLINICAL RESEARCH & DEVSep 06Option Exercise11.301,00011,30028,239Sep 08 04:11 PM
BRYCE RICHARD PAULSR VP, CLINICAL RESEARCH & DEVSep 06Sale100.001,000100,00027,239Sep 08 04:11 PM
Lo StevenChief Commercial OfficerJul 20Sale94.901,990188,85327,220Jul 24 05:16 PM
EYLER CHARLES RSEE REMARKSJul 20Sale95.1566262,99130,018Jul 24 05:14 PM
BRYCE RICHARD PAULSR VP, CLINICAL RESEARCH & DEVJul 20Sale94.481,998188,77727,239Jul 24 05:10 PM
AUERBACH ALAN HPRESIDENT AND CEOJul 20Sale94.7313,1751,248,0054,166,623Jul 24 05:07 PM
BRYCE RICHARD PAULSR VP, CLINICAL RESEARCH & DEVJul 03Option Exercise11.305,00056,50034,237Jul 14 06:01 PM
BRYCE RICHARD PAULSR VP, CLINICAL RESEARCH & DEVJul 03Sale87.105,000435,50029,237Jul 14 06:01 PM